OTHER ASIA

Other Asia comprises all Asian territories excluding China. We have active trading subsidiaries in the Philippines, Taiwan and Malaysia. Therapies that dominate in these regions include Anaesthetics and certain Regional Brands. Our manufacturing facility in India is our primary new product development site.

Key Countries and Territories

Hong Kong
Philippines
Singapore
Taiwan

The South Korean pharmaceutical market is forecast to grow at a CAGR of 6% between 2019 and 2024, reaching Won24,579 billion by 2024.
The Indonesian pharmaceutical market is forecast to grow at a CAGR of 2% between 2019 and 2024, reaching Rp87,578 billion by 2024.

Source: IQVIA Market Prognosis 2020-2024

STATISTICS

Number of products launched:

1

(2019: 2)

Average staff turnover:

19%

(2019: 24%)

Number of product recalls:

Nil

(2019: Nil)

Number of work-related fatalities:

Nil

(2019: Nil)

Number of permanent employees

525

June 2020

482

June 2019

Revenue	2020 R’million	2019 (CER) R’million	Change %
Regional Brands	546	559	(2)
Sterile Focus Brands	835	934	(11)
Anaesthetics Brands	691	749	(8)
Thrombosis Brands	144	185	(22)

Total Commercial Pharmaceuticals	1 381	1 493	(8)
Manufacturing – API	115	121	2
Total	1 496	1 614	(7)

Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.